No description available.

No description available.

No description available.

Les microglies sont les cellules immunitaires du système nerveux central. Elles sont essentielles pour son bon fonctionnement et son homéostasie. Avec l’âge, elles adoptent une morphologie dystrophique accompagnée d’un dérèglement de leurs fonctions homéostatiques. Le dysfonctionnement microglial associé au vieillissement est soupçonné de contribuer à la progression de maladies neurodégénératives. Cependant, la cause de ces changements phénotypiques est peu connue, d’autant plus chez l’humain compte tenu du manque d’accessibilité des microglies humaines âgées vivantes pour le travail moléculaire in vitro. Les travaux présentés dans ce mémoire visent donc le développement d’un modèle cellulaire qui permettrait d’étudier l’impact du vieillissement cellulaire sur la microglie humaine. Dans ce mémoire, nous formulons l’hypothèse que l’induction chimique de la sénescence dans les microglies humaines induira rapidement des caractéristiques associées au vieillissement cellulaire alors que la reprogrammation microgliale directe à partir de cellules de peau d’individus âgés maintiendra la signature associée au vieillissement cellulaire de manière physiologique. Les résultats démontrent que les microglies dans lesquelles la sénescence est chimiquement induite présentent des caractéristiques phénotypiques de vieillissement cellulaire et un dérèglement de leurs fonctions homéostatiques. De plus, les produits cellulaires obtenus par la reprogrammation microgliale directe adoptent plusieurs caractéristiques clés de la microglie, mais certaines conditions de reprogrammation directe doivent encore être déterminées afin d’obtenir un produit cellulaire authentique. Ces techniques fourniront une source renouvelable de microglies humaines âgées pouvant être dérivée de patients, afin d’étudier l’impact du vieillissement sur leurs fonctions physiologiques et sur leur interaction avec les cellules du cerveau dans les maladies neurodégénératives. / Microglia are the resident immune cells of the central nervous system (CNS). They are essential for brain functioning and cerebral homeostasis. With age, they adopt a dystrophic morphology and a disruption of their homeostatic functions occurs. Microglial dysfunction associated with aging is believed to contribute to the progression of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. However, how aging confers to microglia this change in phenotype is still unknown, especially in human given the lack of accessibility of live human aged microglia for in vitro molecular work. As such, the work presented in this Master’s thesis aims the development of a cellular model in which the effect of aging on microglial function can be studied in human microglia. In this paper, we formulate the hypothesis that chemical induction of senescence in human microglia rapidly induces phenotypic characteristics of cellular aging, whereas direct microglial reprogramming from fibroblasts of elderly individuals will maintain the aging signature following cellular conversion. The results obtained show that microglia in which senescence is chemically induced show phenotypic characteristics of cellular aging as well as disruption of their homeostatic functions. On the other hand, cellular product obtained from microglial reprogramming adopt several key features of human microglia, but some direct microglial reprogramming conditions still need to be determined in order to obtain a cell product closely resembling human microglia. These two methods will provide a renewable source of patient-derived aged microglia to study the impact of aging on their physiological functions and on their interaction with other CNS cells in neurodegenerative diseases.

Friedreich's ataxia (FRDA) is the most prevalent inherited ataxia, affecting one in every 50,000 individuals in the United States. This hereditary condition is caused by an abnormal GAA trinucleotide repeat expansion within the first intron of the frataxin gene resulting in decreased levels of the frataxin protein (FXN). Insufficient cellular frataxin levels results in iron accumulation, increased reactive oxygen species production and mitochondrial dysfunction. Tissues most heavily impacted are those most dependent on oxidative phosphorylation as an energy source and include the nervous system and muscle tissue. This is evident in the clinical phenotype which includes muscle weakness, ataxia, neurodegeneration and cardiomyopathy. However, there has been a lack of data regarding the cell type specific contributions in FRDA pathogenesis. We generated a cohort of induced pluripotent stem cells (iPSCs) consisting of FRDA patient lines, CRISPR-Cas9 edited controls, carriers and non-related controls. Our preliminary data identified a hyperinflammatory microglial phenotype with extensive defects in mitochondrial function; since microglia are the primary innate immune cell of the brain, we hypothesized microglia may decrease neuronal viability which contributes to FRDA pathology. To investigate this, the iPSC cohort was utilized to generate microglia (iMGs) and neurons to better understand microglia-mediated neurodegeneration and how this contributes to pathology. An in vitro co-culture model composed of neurons, astrocytes and microglia was employed to better understand microglia-neuronal communication in FRDA. Healthy neurons co-cultured with FRDA iMG or with FRDA iMG-conditioned media demonstrated higher incidences of caspase-3 mediated apoptosis. These findings were recapitulated in vivo as xenotransplantation of FRDA microglia progenitors into a murine model resulted in reduced Purkinje cell survival in the cerebellum. Previous research has demonstrated the therapeutic potential of wildtype microglia to rescue the FRDA phenotype in the Y8GR mouse model of FRDA. To further explore the potential mechanisms behind this rescue, the delivery of mitochondria and FXN to FRDA microglia and neurons was investigated. CRISPR-Cas9 edited microglia demonstrated transfer of healthy mitochondria to FRDA microglia and neurons in an in vitro co-culture model. To investigate the transfer of frataxin protein, an FRDA iPSC line was transduced with an FXN-GFP lentivirus. Restoring FXN expression was demonstrated to rescue the FRDA microglial morphological phenotype. FXN-GFP microglia demonstrated transfer of frataxin protein to FRDA microglia suggesting the potential role of microglia as a therapeutic vehicle in FRDA. Together these findings show that FRDA microglia have a deleterious effect on neuronal viability, while healthy microglia may work as a therapeutic vehicle through the delivery of mitochondria and frataxin to FRDA cells.

I hjärnan finns neuron och gliaceller. Förut trodde man att neuroner var dem enda som hade en viktig funktion i hjärnan men på senare tid har upptäckt att gliaceller har en större betydande roll än man tidigare trott. Gliaceller är ett samlingsnamn som innefattar bland annat microglia celler, oligodendrocyter och astrocyter. Östrogen är ett steroidhormon som har många viktiga funktioner i kroppen som bland annat reproduktionen, immunförsvaret, skelettet och endokrina system. Östrogen binder till östrogenreceptorer och de finns 3 stycken olika som kallas för östrogenreceptor alfa (α), östrogenreceptor beta (β) och G-proteinkopplade östrogenreceptor (GRP30). Alla dessa östrogenreceptorer har man funnit i hjärnan. Syftet med detta projektarbete är att ge en djupare förståelse om östrogens signalering i hjärnans gliaceller och om östrogens signalering kan ge någon relevant funktion till framtida farmakologiska behandlingar.  Systematisk litteraturstudie gjordes och sökningar på databasen PubMed. Begränsade antalet träffar med sökord, inklusionskriterier och exklusionskriterier. Artiklar granskades sedan via ett urvalssystem och relevanta artiklar användes för att besvara syfte och frågeställningar.  Östrogensignaleringen på gliaceller har många olika effekter. En signalering på östrogenreceptor β på oligodendrocyter leder till mognad, differentiering, bättre överlevd och att remyeliniseringen aktiverades. Medan en östrogens signalering på microglia cellens östrogenreceptorer α, β och GRP30 leder dämpning av inflammation och förbättrad kognitiv funktion. Östrogensignaleringen på astrocyter ger flera olika effekter såsom metabolismen av glukos, progesteron syntesen, glutamattransportören GLT-1, tillväxtfaktorn TGF-α, upptaget av glutamat samt ökad proteinproduktion av AMPA-receptor. Den nya kunskapen om östrogens signalering på hjärnans gliaceller kan leda till framtida farmakologiska behandlingar vid hjärnskada och ischemisk stroke. Östrogenet har visat på neuronskyddande effekter via signalering på gliaceller. Svagheten är att de endast är djurstudier som ligger till grund för kunskapen om östrogens signalering på gliaceller. I framtiden skulle det behövas styrkas med studier gjorda på människa. En styrka är att djurstudierna ger en fingervisning om östrogen signaleringen eftersom hjärnans uppbyggnad är likvärdig.

De plus en plus d’études montrent un lien entre la teneur en vitamine K (VK) dans l’organisme et la cognition. Certaines études effectuées in vitro on montré l’effet de la VK au niveau moléculaire, mais très peu in vivo. Une étude récente de Tamadon-Nejad a montré qu’un traitement de 14mg/kg/jr de warfarine, un antagoniste de la VK, administré simultanément à des injections sous-cutanées de 85mg/kg/jr de phylloquinone entrainait une diminution significative de la concentration de MK-4 du cerveau, résultant en une diminution significative du statut vitaminique K au cerveau, une altération de la cognition, du comportement exploratoire et de la locomotion [1]. Dans la présente étude, le traitement de Tamadon-Nejad a été modifié et les doses de phylloquinone ont été augmentées à 120mg/kg/jr (WVK) ce qui a maintenu une diminution significative de la concentration de la concentration de MK-4 dans le cerveau, mais a entrainé une surcompensation par la phylloquinone, résultant en une augmentation significative du statut vitaminique K au cerveau. Ce statut a été associé à une mémoire de reconnaissance intacte et corrélé à une amélioration de la mémoire spatiale des rats WVK. Le traitement a aussi été associé à une augmentation significative de l’anxiété et au rétablissement du comportement exploratoire et de la locomotion des rats WVK comparativement à l’étude de Tamadon-Nejad [1]. Dans l’hippocampe des rats WVK, l’amélioration de la cognition et le rehaussement du statut vitaminique K du cerveau n'ont pas induit de variation significative de l’activation des protéines dépendantes de la VK Gas6 et Protéine S, mais ont été associés à une augmentation significative de l’activation de la voie MAPK, à une inhibition de l’apoptose et à une présence accrue de la microglie. En somme, cette étude confirme le rôle modulateur de la VK dans le cerveau sur la cognition et la survie cellulaire. / There is growing evidence that vitamin K (VK) plays a role in cognition. Some in vitro studies have shown how VK affects different molecular pathways in brain cells, but few in vivo studies have been conducted. Recently, a study from Tamadon- Nejad showed that a treatment of 14mg/kg/d of warfarine, a VK antagonist, given simultaneously with subcutaneous injections of 85mg/kg/d lead to a significant decrease in MK-4 concentration in brain, resulting in a significant decrease of VK status in brain, and perturbation in cognition, exploratory behaviour and locomotion [1]. In the present study, we modified the treatment used in Tamadon-Nejad and increased the phylloquinone doses to 120mg/kg/d which maintained the significant decrease in MK-4 concentration in brain, but lead to an overcompensation of phylloquinone that resulted in an increase of VK status in brain. This status was associated with an intact recognition memory and correlated with an improvement in spatial memory of WVK rats. The treatment was also associated with a significant increase in anxiety and recovery of exploratory behavior and locomotion compared to rats in the Tamadon-Nejad study [1]. In WVK rat hippocampi, cognition improvement and increased VK status were not associated with significant variation in VK dependant proteins (VKDP) Gas6 and Protein S activation, but were associated with an increase in the MAPK activation pathway, an inhibition of apoptosis and, an increased presence of microglia. In summary, this study confirms the modulatory role of VK in brain in cognition and cell survival.

No description available.

La sclérose en plaques (SEP) est une maladie inflammatoire démyélinisante et neurodégénérative du système nerveux central (SNC). Les cellules T activées qui expriment le PD-1 sont inhibées via l’interaction avec l’un des ligands: PD-L1 ou PD-L2. Des études effectuées chez le modèle murin de la SEP, l’encéphalomyélite auto-immune expérimentale (EAE), ont démontré que l’interaction du PD-1 avec ses ligands contribue à atténuer la maladie. Toutefois, le rôle du PD-1 et de ses ligands dans la pathogenèse de la SEP chez l’humain et dans le modèle murin n’a pas été complètement élucidé. Nous avons déterminé que plusieurs cellules du SNC humain peuvent exprimer les ligands du PD-1. Les astrocytes, les microglies, les oligodendrocytes et les neurones expriment faiblement le PD-L1 dans des conditions basales mais augmentent de façon significative cette expression en réponse à des cytokines inflammatoires. Le blocage de l’expression du PD-L1 par les astrocytes à l’aide de siRNA spécifiques mène à l’augmentation significative des réponses des cellules T CD8+ (prolifération, cytokines, enzymes lytiques). Nos résultats établissent ainsi que les cellules gliales humaines peuvent exprimer des niveaux suffisants de PD-L1 en milieu inflammatoire pour inhiber les réponses des cellules T CD8+. Notre analyse de tissus cérébraux post-mortem par immunohistochimie démontre que dans les lésions de la SEP les niveaux de PD-L1 sont significativement plus élevés que dans les tissus de témoins; les astrocytes et les microglies/macrophages expriment le PD-L1. Cependant, plus de la moitié des lymphocytes T CD8+ ayant infiltré des lésions de SEP n’expriment pas le récepteur PD-1. Au cours du développement de l’EAE, les cellules du SNC augmentent leur niveau de PD-L1. Le PD-1 est fortement exprimé par les cellules T dès le début des symptômes, mais son intensité diminue au cours de la maladie, rendant les cellules T insensibles au signal inhibiteur envoyé par le PD-L1. Nous avons observé que les cellules endothéliales humaines formant la barrière hémato-encéphalique (BHE) expriment de façon constitutive le PD-L2 mais pas le PD-L1 et que l’expression des deux ligands augmente dans des conditions inflammatoires. Les ligands PD-L1 et PD-L2 exprimés par les cellules endothéliales ont la capacité de freiner l’activation des cellules T CD8+ et CD4+, ainsi que leur migration à travers la BHE. L’endothélium du cerveau des tissus normaux et des lésions SEP n’exprime pas des taux détectables de PD-L1. En revanche, tous les vaisseaux sanguins des tissus de cerveaux normaux sont positifs pour le PD-L2, alors que seulement la moitié de ceux-ci expriment le PD-L2 dans des lésions SEP. Nos travaux démontrent que l’entrée des cellules T activées est contrôlée dans des conditions physiologiques grâce à la présence du PD-L2 sur la BHE. Cependant, l’expression plus faible du PD-L2 sur une partie des vaisseaux sanguins dans les lésions SEP nuit au contrôle de la migration des cellules immunes. De plus, une fois dans le SNC, les cellules T CD8+ étant dépourvues du PD-1 ne peuvent recevoir le signal inhibiteur fourni par le PD-L1 fortement exprimé par les cellules du SNC, leur permettant ainsi de rester activées. / Multiple sclerosis (MS) is an inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS). Responses of activated T cells are suppressed upon engagement of the receptor programmed cell death-1 (PD-1) with its ligands (PD-L1 and PD-L2). Experiments using the mouse model of MS, experimental autoimmune encephalomyelitis (EAE), have demonstrated that the PD-1/PD-Ls interaction contributes to attenuate disease severity. However, the expression and the role of PD-1 and PD-Ls have been partially documented in inflammatory murine models and human CNS data are still incomplete. We determined that primary cultures of human astrocytes, microglia, oligodendrocytes, or neurons expressed low or undetectable PD-L1 levels under basal conditions, but inflammatory cytokines significantly induced such expression, especially on astrocytes and microglia. Blocking PD-L1 expression in astrocytes using specific siRNA in co-culture led to significantly increased CD8 T cell responses (proliferation, cytokines, lytic enzyme). Thus, our results establish that inflamed human glial cells can express sufficient and functional PD-L1 to inhibit CD8 T cell responses. Extensive immunohistochemical analysis of post-mortem brain tissues demonstrated a significantly greater PD-L1 expression in MS lesions compared to control tissues, which co-localized with astrocyte and microglia/macrophage cell markers. However, more than half of infiltrating CD8 T lymphocytes in MS lesions did not express PD-1, the cognate receptor. Similar results were obtained in EAE mice. Even though CNS cells expressed PD-L1 at the peak of the disease, PD-1 intensity on infiltrating T cells decreased throughout EAE disease development. This reduction of PD-1 level on activated T cells prevented these cells to receive PD-L1 inhibitory signal. We also investigated whether human brain endothelial cells (HBECs), which form the blood brain barrier (BBB), can express PD-L1 or PD-L2 and thereby modulate T cells. HBECs expressed PD-L2 under basal conditions, whilst PD-L1 was not detected. Both ligands were up-regulated under inflammatory conditions. Blocking PD-L1 and PD-L2 led to increased transmigration and enhanced responses by human CD8 T cells in co-culture assays. Similarly, PD-L1 and PD-L2 blockade significantly increased CD4 T cell transmigration. Brain endothelium in normal tissues and MS lesions did not express detectable PD-L1; in contrast, all blood vessels in normal brain tissues were PD-L2-positive, while only about 50% expressed PD-L2 in MS lesions. Therefore, our results demonstrate that under basal conditions, PD-L2 expression by HBECs impedes the migration of activated immune T cells through the BBB, and inhibits their activation. However, such impact is impaired in MS lesions due to down-regulation of PD-L2 levels on the endothelium. The majority of infiltrating CD8 T cells is devoid of PD-1, thus insensitive to PD-L1 inhibitory signal providing by CNS cells once they have entered the CNS.

Entre os PRRs (receptores de reconhecimento padrão), NOD-like receptors (NLRs), tal como NOD2, são responsáveis pela detecção intracelular de muramil dipeptídeo (MDP); padrão molecular associado a patógeno (PAMP), encontrado no peptidoglicano (PGN) de praticamente todas bactérias GRAM positiva e negativa. Após o reconhecimento e estimulação por MDP, NOD2 recruta diretamente a serina-treonina quinase RIPK2, uma proteína adaptadora importante na ativação de NF?B mediada por NOD2. A expressão de NOD2 foi descrita em macrófagos e em outras células. Além disso, trabalhos anteriores indicaram que PRRs desempenham papel crucial na ativação de células gliais da medula espinal, na indução e manutenção da dor inflamatória crônica e dor neuropática. No presente estudo, avaliamos o papel de NOD2 na modulação da sensibilidade à dor, focando sua importância na ativação de células da glia da medula espinal, bem como a sua via de sinalização (RIPK2) e liberação de citocinas pró-nociceptivas, como o fator de necrose tumoral alfa (TNF-?), interleucina-6 (IL-6) e interleucina-1 beta (IL-1?). Os resultados demonstram que camundongos selvagens tratados com MDP, apresentaram diminuição no limiar nociceptivo mecânico (pico entre 3 e 5 horas) comparado com o grupo controle (veículo), retornando ao basal após 48 horas. Além disso, camundongos NOD2-/- , RIPK2-/- , TNFR1/2-/- e IL-6 -/- tratados com MDP não diferiram o limiar nociceptivo mecânico, comparado com seus respectivos grupos controle (veículo). Entretanto, camundongos TNFR1- /- , CCR2-/- , TLR4-/- , MyD88-/- e TRIF-/- tratados com MDP, apresentaram diminuição no limiar nociceptivo mecânico similar aos camundongos selvagens tratados com MDP. Adicionalmente, o pré-tratamento de camundongos selvagens com IL-1ra, propentofilina, minociclina, fluorocitrato e SB 203580 inibiu o desenvolvimento da hipersensibilidade mecânica induzida por MDP. Estes dados sugerem que a ativação do sensor intracellular NOD2 esta presente em células da glia da medula espinal e estimula a ativação das vias de sinalização RIPK2 e p38 MAPK com subsequente produção de IL-1?, IL-6 e TNF?, por uma via de sinalização independente de TLR4, MyD88 e TRIF. Finalmente, estes mecanismos contribuem para o processo de hipersensibilidade mecânica durante a neuropatia periférica e representam uma nova abordagem para elucidar os mecanismos envolvidos na fisiopatologia da dor crônica. / Among PRRs (pattern recognition receptors), NOD-like receptors (NLRs), such as NOD2 are responsible by intracellular detection of muramyl dipeptide (MDP); pathogen-associated molecular pattern (PAMP) found in the peptidoglycan (PGN) from virtually all gram positive and gram negative bacteria. Upon recognition and stimulation by MDP, NOD2 recruits directly the receptor-interacting serine/threonine-protein kinase 2 (RIPK2), an adaptor protein important in the NOD2-mediated NF?B activation. The expression of NOD2 has been described in macrophages and other cells. Moreover, previous work has indicated that PRRs play a crucial role in the activation of spinal cord glial cells, in the induction and maintenance of chronic inflammatory and neuropathic pain. In the present study, we aimed to evaluate the role of NOD2 in the modulation of pain sensitivity, focusing on its importance in the activation of spinal cord glial cells, as well as its signaling pathway (RIPK2) and release of pro-nociceptive cytokines, such as tumour necrosis factor-alpha (TNF-?), interleukin-6 (IL-6) and interleukin-1beta (IL-1?). The results demonstrate that WT mice treated with MDP showed a decrease in mechanical nociceptive threshold (peak 3 to 5 hours) compared with the control group (vehicle), returning to the base line after 48 hours. Furthermore, NOD2-/- , RIPK2-/- , TNFR1/2-/- and IL-6 -/- mice treated with MDP did not differ the mechanical nociceptive threshold compared with their respective control groups (vehicle). However, TNFR1-/- , CCR2-/- , TLR4-/- , MyD88-/- and TRIF-/- mice treated MDP, showed a decrease in mechanical nociceptive threshold similar to WT mice treated with MDP. In addition, the pretreatment of WT mice with IL-1ra, propentofylline, minocycline, fluorocitrate and SB 203580 inhibited the development of mechanical hypersensitivity induced by MDP. These data suggest that activation of the intracellular sensor NOD2 present in spinal cord glial cells stimulates the activation of RIPK2 and p38 MAPK signaling pathways and subsequent production of IL-1?, IL-6 and TNF?, in a TLR4-, MyD88- and TRIF-independent signaling pathway. Finally, these mechanisms contribute to the process of mechanical hypersensitivity during peripheral neuropathy and represent a novel approach for elucidating the mechanisms underlying pathophysiology of chronic pain.